What is Nutromics?
Nutromics is a pioneering force in the healthcare sector, specifically targeting the advancement of Continuous Molecular Monitoring. The company is developing innovative lab-on-a-patch technology designed to provide real-time, continuous tracking of vital health indicators. By moving beyond the limitations of traditional, episodic lab diagnostics, Nutromics aims to deliver actionable trend data that empowers healthcare providers to make more informed clinical decisions.
This technology addresses a significant gap in current diagnostic workflows, offering a pathway to improved patient outcomes and reduced systemic healthcare costs. By focusing on dynamic monitoring, Nutromics is effectively positioning itself as a key player in the shift toward proactive, data-driven patient care.
How much funding has Nutromics raised?
Nutromics has raised a total of $19.7M across 2 funding rounds:
Unspecified
$5.7M
Other Financing Round
$14M
Unspecified (2021): $5.7M with participation from Artesian Capital Partners
Other Financing Round (2022): $14M led by Artesian Investments, VU Venture Partners, and Dexcom Ventures
Key Investors in Nutromics
Artesian Capital Partners
Artesian Capital Partners is an integrated firm that provides innovative financing solutions and engineering expertise to support sustainable infrastructure and industrial growth.
VU Venture Partners
VU Venture Partners is a global multi-stage venture capital firm with a strong focus on the healthcare and frontier technology sectors, known for supporting high-growth startups through their entire lifecycle.
Dexcom Ventures
Dexcom Ventures is the strategic investment arm of a leading continuous glucose monitoring company, focusing on advancing technologies that improve the lives of people with diabetes and other chronic conditions.
What's next for Nutromics?
With the recent capital deployment, Nutromics is expected to focus on the clinical validation and commercial scaling of its lab-on-a-patch solution. The strategic backing from specialized healthcare and venture investors suggests a clear roadmap toward market entry and regulatory milestones. Future efforts will likely center on expanding the diagnostic capabilities of their patch, potentially broadening the scope of monitorable health conditions to capture a larger share of the diagnostic market.
As the company matures, the focus will shift toward integrating these diagnostic insights into existing hospital information systems, thereby cementing its role as an essential component of modern healthcare infrastructure.
